{ "company": "Revvity", "ticker": "RVTY", "period": { "from": "2026-02-28", "to": "2026-03-30", "days": 30 }, "sentiment_breakdown": { "positive": 36, "negative": 19, "neutral": 37 }, "synthesis": { "executive_summary": "**Executive Summary: Revvity (RVTY) Sentiment Analysis**\n\nSentiment analysis for Revvity (RVTY) from February 28 to March 30, 2026, indicates a cautiously positive outlook. Out of 92 monitored items, 36 were positive, 19 were negative, and 37 were neutral. Key positive drivers include an analyst upgrade from Nephron Research, signaling increased confidence in RVTY shares, alongside broader market opportunities in therapeutic applications like oligonucleotides and the COVID-19 tests market. Scientific advancements in areas such as tumor growth inhibition and vaccine development also contributed to the positive sentiment.\n\nConversely, the most significant negative sentiment stemmed from reports highlighting pressure on Revvity's stock due to a slowdown in the broader life sciences sector, particularly ahead of its Q4 earnings release. This slowdown is attributed to reduced research funding and biopharma spending cuts, directly impacting the company's financial outlook. Other negative mentions included complex scientific research findings and a report on the epigenetics market, despite its projected growth, which was categorized as negative within the analysis. Investors should monitor the upcoming Q4 results for further clarity on sector headwinds and their impact on Revvity's performance.", "key_findings": [ "✓ Oligonucleotides Global Markets, 2022-2024 & 2025-2030, Profiles of Major Players - Alnylam Pharmaceuticals, Biogen/Ionis Pharmaceuticals, Novartis, and Sarepta Therapeutics", "✓ Nephron Research gets more bullish on Revvity, upgrades shares", "✓ COVID-19 Tests Market Report 2025: Segments, Share, Regulatory, Reimbursement, and Forecasts to 2036", "✗ The E3 ubiquitin ligase mechanism specifying targeted microRNA degradation", "✗ Ectopic NMDAR expression in cancer unmasks germline-encoded autoimmunity", "✗ Epigenetics Market to Surpass US $35.84 Billion by 2031, Fuelled by Rising Prevalence of Cancer - Latest Industry Research by The Insight Partners" ], "overall_sentiment": "positive" }, "top_positive": [ { "title": "Oligonucleotides Global Markets, 2022-2024 & 2025-2030, Profiles of Major Players - Alnylam Pharmaceuticals, Biogen/Ionis Pharmaceuticals, Novartis, and Sarepta Therapeutics", "date": "2026-03-02", "source": "news", "score": 1.0 }, { "title": "Nephron Research gets more bullish on Revvity, upgrades shares", "date": "2026-03-26", "source": "news", "score": 0.991 }, { "title": "COVID-19 Tests Market Report 2025: Segments, Share, Regulatory, Reimbursement, and Forecasts to 2036", "date": "2026-03-12", "source": "news", "score": 0.859 }, { "title": "Catabolism of extracellular glutathione supplies cysteine to support tumours", "date": "2026-03-18", "source": "news", "score": 0.856 }, { "title": "A structure-based mRNA vaccine for Nipah virus in healthy adults: a phase 1 trial", "date": "2026-03-12", "source": "news", "score": 0.852 }, { "title": "Send a Free Postcard at PAX East 💌 Pelican Post (Booth #20084)", "date": "2026-03-25", "source": "reddit", "score": 0.818 }, { "title": "10 Best Mid Cap Value Stocks to Buy in 2026", "date": "2026-03-25", "source": "alpha_vantage", "score": 0.765 }, { "title": "10 Best Mid Cap Value Stocks to Buy in 2026", "date": "2026-03-25", "source": "alpha_vantage", "score": 0.765 }, { "title": "10 Best Mid Cap Value Stocks to Buy in 2026", "date": "2026-03-25", "source": "alpha_vantage", "score": 0.765 }, { "title": "Revvity Inc. stock outperforms competitors on strong trading day", "date": "2026-03-23", "source": "alpha_vantage", "score": 0.711 } ], "top_negative": [ { "title": "The E3 ubiquitin ligase mechanism specifying targeted microRNA degradation", "date": "2026-03-18", "source": "news", "score": -0.778 }, { "title": "Ectopic NMDAR expression in cancer unmasks germline-encoded autoimmunity", "date": "2026-03-25", "source": "news", "score": -0.66 }, { "title": "Epigenetics Market to Surpass US $35.84 Billion by 2031, Fuelled by Rising Prevalence of Cancer - Latest Industry Research by The Insight Partners", "date": "2026-03-11", "source": "news", "score": -0.66 }, { "title": "Inhalable Ultrasound Contrast Agent with Induced Microbubble Destruction and Associated Biological Effects on the Respiratory Epithelium, In Vitro.", "date": "2026 Mar 9", "source": "pubmed", "score": -0.572 }, { "title": "Revvity Inc. stock faces pressure amid life sciences sector slowdown as Q4 earnings loom", "date": "2026-03-26", "source": "alpha_vantage", "score": -0.477 }, { "title": "A Look At Mettler-Toledo International (MTD) Valuation After Recent Institutional Selling And Sector Weakness", "date": "2026-03-12", "source": "alpha_vantage", "score": -0.421 }, { "title": "Revvity Inc. stock faces pressure amid life sciences sector slowdown and looming Q4 earnings test", "date": "2026-03-25", "source": "alpha_vantage", "score": -0.402 }, { "title": "Analysts Have Conflicting Sentiments on These Healthcare Companies: Revvity (RVTY) and Candel Therapeutics (CADL)", "date": "2026-03-14", "source": "alpha_vantage", "score": -0.402 }, { "title": "Why (RVTY) Price Action Is Critical for Tactical Trading", "date": "2026-03-21", "source": "alpha_vantage", "score": -0.318 }, { "title": "Revvity Inc. Stock: Navigating Life Sciences Headwinds and Q4 Earnings Pressure Ahead", "date": "2026-03-26", "source": "alpha_vantage", "score": -0.296 } ], "raw_data": { "total_items": 92, "items": [ { "source": "news", "source_name": "Yahoo Entertainment", "title": "Stifel Maintains a Hold Rating on Revvity (RVTY)", "description": "", "url": "https://consent.yahoo.com/v2/collectConsent?sessionId=1_cc-session_5264e652-64a8-4995-bdc5-fa1ad7e19dbd", "date": "2026-03-27", "published_at": "2026-03-27T07:29:27Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Thefly.com", "title": "Nephron Research gets more bullish on Revvity, upgrades shares", "description": "See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual investors, professional money managers, active traders, and corpor…", "url": "https://www.thefly.com/RVTY", "date": "2026-03-26", "published_at": "2026-03-26T11:13:51Z", "sentiment": { "label": "positive", "score": 0.991, "confidence": 0.99 } }, { "source": "news", "source_name": "Nature.com", "title": "Ectopic NMDAR expression in cancer unmasks germline-encoded autoimmunity", "description": "NMDAR expression is sufficient to induce B cell recruitment and affinity maturation, resulting in receptor-modulating antibodies that connect anti-cancer immunity and autoimmunity.", "url": "https://www.nature.com/articles/s41586-026-10278-0", "date": "2026-03-25", "published_at": "2026-03-25T00:00:00Z", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "news", "source_name": "Yahoo Entertainment", "title": "Is Revvity Stock Underperforming the S&P 500?", "description": "", "url": "https://consent.yahoo.com/v2/collectConsent?sessionId=1_cc-session_0da74d95-ac07-4f8b-a52f-bf2fc7eb9b22", "date": "2026-03-20", "published_at": "2026-03-20T10:12:04Z", "sentiment": { "label": "negative", "score": -0.2, "confidence": 0.2 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Genomics Market to Reach USD 85.09 Billion by 2030 | MarketsandMarkets™", "description": "Advancements in NGS, AI-driven bioinformatics, and expanding precision medicine initiatives are positioning genomics as a strategic pillar in modern healthcare, diagnostics, and drug discovery. Advancements in NGS, AI-driven bioinformatics, and expanding prec…", "url": "https://www.globenewswire.com/news-release/2026/03/19/3259211/0/en/Genomics-Market-to-Reach-USD-85-09-Billion-by-2030-MarketsandMarkets.html", "date": "2026-03-19", "published_at": "2026-03-19T14:30:00Z", "sentiment": { "label": "neutral", "score": 0.026, "confidence": 0.03 } }, { "source": "news", "source_name": "Nature.com", "title": "The E3 ubiquitin ligase mechanism specifying targeted microRNA degradation", "description": "Target-directed microRNA degradation is driven by the atypical ZSWIM8–CUL3 E3 ubiquitin ligase that uses a two-RNA-factor authentication mechanism to specifically recognize AGO–miRNA–trigger RNA complexes and polyubiquitylate AGO.", "url": "https://www.nature.com/articles/s41586-026-10232-0", "date": "2026-03-18", "published_at": "2026-03-18T00:00:00Z", "sentiment": { "label": "negative", "score": -0.778, "confidence": 0.78 } }, { "source": "news", "source_name": "Nature.com", "title": "Catabolism of extracellular glutathione supplies cysteine to support tumours", "description": "Catabolism of extracellular glutathione by γ-glutamyltransferases supports tumour growth and survival, and pharmacological targeting of these enzymes slows tumour growth.", "url": "https://www.nature.com/articles/s41586-026-10268-2", "date": "2026-03-18", "published_at": "2026-03-18T00:00:00Z", "sentiment": { "label": "positive", "score": 0.856, "confidence": 0.86 } }, { "source": "news", "source_name": "Yahoo Entertainment", "title": "Emerald Growth Equity Strategy Sold Revvity (RVTY) in Q4", "description": "", "url": "https://consent.yahoo.com/v2/collectConsent?sessionId=1_cc-session_649a11d8-8503-4978-8942-c9108f173957", "date": "2026-03-16", "published_at": "2026-03-16T13:58:38Z", "sentiment": { "label": "positive", "score": 0.382, "confidence": 0.38 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Global In Vitro Diagnostics Market to Reach USD 157.63 Billion by 2030 | MarketsandMarkets™", "description": "Market Expansion Accelerates as Clinical Laboratories and Healthcare Systems Prioritize Rapid Diagnostics, Automation, and Early Disease Detection Market Expansion Accelerates as Clinical Laboratories and Healthcare Systems Prioritize Rapid Diagnostics, Autom…", "url": "https://www.globenewswire.com/news-release/2026/03/12/3254849/0/en/Global-In-Vitro-Diagnostics-Market-to-Reach-USD-157-63-Billion-by-2030-MarketsandMarkets.html", "date": "2026-03-12", "published_at": "2026-03-12T14:30:00Z", "sentiment": { "label": "neutral", "score": 0.026, "confidence": 0.03 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "COVID-19 Tests Market Report 2025: Segments, Share, Regulatory, Reimbursement, and Forecasts to 2036", "description": "Opportunities in the COVID-19 tests market include developing innovative products, leveraging global and regional trends, understanding competitive dynamics, and accessing country-specific regulatory and reimbursement insights. Companies can capitalize on mar…", "url": "https://www.globenewswire.com/news-release/2026/03/12/3254589/28124/en/COVID-19-Tests-Market-Report-2025-Segments-Share-Regulatory-Reimbursement-and-Forecasts-to-2036.html", "date": "2026-03-12", "published_at": "2026-03-12T12:04:00Z", "sentiment": { "label": "positive", "score": 0.859, "confidence": 0.86 } }, { "source": "news", "source_name": "Nature.com", "title": "A structure-based mRNA vaccine for Nipah virus in healthy adults: a phase 1 trial", "description": "In this phase 1, open-label dose-escalation study in healthy adults found that the mRNA vaccine (mRNA-1215), encoding the Nipah virus Malaysian strain chimeric pre-fusion F protein linked to glycoprotein G, was safe and induced elevated immune responses at 1 …", "url": "https://www.nature.com/articles/s41591-026-04265-1", "date": "2026-03-12", "published_at": "2026-03-12T00:00:00Z", "sentiment": { "label": "positive", "score": 0.852, "confidence": 0.85 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Epigenetics Market to Surpass US $35.84 Billion by 2031, Fuelled by Rising Prevalence of Cancer - Latest Industry Research by The Insight Partners", "description": "Epigenetics Market is projected to grow from US$ 11.12 billion in 2024 to US$ 35.84 billion by 2031, registering a CAGR of 18.3% ...", "url": "https://www.globenewswire.com/news-release/2026/03/11/3253649/0/en/Epigenetics-Market-to-Surpass-US-35-84-Billion-by-2031-Fuelled-by-Rising-Prevalence-of-Cancer-Latest-Industry-Research-by-The-Insight-Partners.html", "date": "2026-03-11", "published_at": "2026-03-11T11:20:00Z", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Gene Expression Analysis Market Size to Reach USD 11.53 Billion by 2035; Growth is Propelling Owing to Continuous Growth of Genomics Research Globally | SNS Insider", "description": "Gene Expression Analysis Market to reach USD 11.53 billion by 2035, driven by genomics research and precision medicine adoption....", "url": "https://www.globenewswire.com/news-release/2026/03/09/3251600/0/en/Gene-Expression-Analysis-Market-Size-to-Reach-USD-11-53-Billion-by-2035-Growth-is-Propelling-Owing-to-Continuous-Growth-of-Genomics-Research-Globally-SNS-Insider.html", "date": "2026-03-09", "published_at": "2026-03-09T09:29:00Z", "sentiment": { "label": "positive", "score": 0.66, "confidence": 0.66 } }, { "source": "news", "source_name": "Yahoo Entertainment", "title": "Bretton Fund Exited Revvity (RVTY) in 2025", "description": "", "url": "https://consent.yahoo.com/v2/collectConsent?sessionId=1_cc-session_81f2d4b0-17a5-44ea-b69b-69b8a7e86602", "date": "2026-03-05", "published_at": "2026-03-05T12:48:58Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Personalized Medicine Biomarkers Market Outlook 2026-2034: Applications Beyond Cancer Into Diseases Like Neurodegeneration and Cardiometabolic Conditions Presents New Opportunities", "description": "The personalized medicine biomarkers market offers significant opportunities driven by advancements in precision healthcare. Key opportunities include the widespread adoption in oncology and emerging use in neurology and cardiology, the demand for minimally i…", "url": "https://www.globenewswire.com/news-release/2026/03/04/3249525/28124/en/Personalized-Medicine-Biomarkers-Market-Outlook-2026-2034-Applications-Beyond-Cancer-Into-Diseases-Like-Neurodegeneration-and-Cardiometabolic-Conditions-Presents-New-Opportunities.html", "date": "2026-03-04", "published_at": "2026-03-04T15:43:00Z", "sentiment": { "label": "positive", "score": 0.637, "confidence": 0.64 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Oligonucleotides Global Markets, 2022-2024 & 2025-2030, Profiles of Major Players - Alnylam Pharmaceuticals, Biogen/Ionis Pharmaceuticals, Novartis, and Sarepta Therapeutics", "description": "The oligonucleotides market offers opportunities in therapeutic applications, particularly for untreated diseases using ASOs, siRNA, and aptamers, with leaders like Alnylam driving innovation. Growth also spans diagnostics and research, supported by evolving …", "url": "https://www.globenewswire.com/news-release/2026/03/02/3247090/28124/en/Oligonucleotides-Global-Markets-2022-2024-2025-2030-Profiles-of-Major-Players-Alnylam-Pharmaceuticals-Biogen-Ionis-Pharmaceuticals-Novartis-and-Sarepta-Therapeutics.html", "date": "2026-03-02", "published_at": "2026-03-02T09:05:00Z", "sentiment": { "label": "positive", "score": 1.0, "confidence": 1.0 } }, { "source": "alpha_vantage", "title": "Revvity Vote On Special Meetings And Stock Retention Meets Valuation Gap", "url": "https://www.sahmcapital.com/news/content/revvity-vote-on-special-meetings-and-stock-retention-meets-valuation-gap-2026-03-28", "date": "2026-03-29", "summary": "Revvity (NYSE:RVTY) is preparing for its annual meeting on April 28, 2026, where shareholders will vote on key proposals including a bylaw change allowing holders of 25% of shares to call special meetings and activist-backed tighter executive stock retention requirements. The article highlights that Revvity's shares are significantly undervalued compared to analyst targets and Simply Wall St's fair value, despite recent momentum showing a 14% decline over 30 days. These votes are crucial as they", "sentiment_score": 0.033114, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.402, "confidence": 0.4 } }, { "source": "alpha_vantage", "title": "SG Americas Securities LLC Boosts Stock Holdings in Revvity Inc. $RVTY", "url": "https://www.marketbeat.com/instant-alerts/filing-sg-americas-securities-llc-boosts-stock-holdings-in-revvity-inc-rvty-2026-03-29/", "date": "2026-03-29", "summary": "SG Americas Securities LLC significantly increased its stake in Revvity Inc. (NYSE:RVTY) by 186.8% in Q4 2025, now holding 123,173 shares valued at $11.92 million. Other institutional investors also adjusted their positions, with large increases from EdgePoint Investment Group Inc., Norges Bank, Allspring Global Investments Holdings LLC, Dimensional Fund Advisors LP, and Invesco Ltd. Analysts currently give RVTY an average \"Hold\" rating with an average price target of $113.67, though some firms ", "sentiment_score": 0.067919, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.542, "confidence": 0.54 } }, { "source": "alpha_vantage", "title": "Revvity Vote On Special Meetings And Stock Retention Meets Valuation Gap", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-rvty/revvity/news/revvity-vote-on-special-meetings-and-stock-retention-meets-v", "date": "2026-03-28", "summary": "Revvity (NYSE:RVTY) is holding its annual meeting on April 28, 2026, where shareholders will vote on a bylaw change allowing holders of 25% of shares to call special meetings and on activist-backed proposals for executive stock retention. These votes, alongside the company's current valuation gap and recent stock decline, will determine the balance between board flexibility and shareholder influence. The article highlights that Revvity's shares are trading significantly below analyst targets and", "sentiment_score": -0.070672, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.402, "confidence": 0.4 } }, { "source": "alpha_vantage", "title": "Revvity Vote On Special Meetings And Stock Retention Meets Valuation Gap", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-rvty/revvity/news/revvity-vote-on-special-meetings-and-stock-retention-meets-v/amp", "date": "2026-03-28", "summary": "Revvity (NYSE:RVTY) will hold its annual meeting on April 28, 2026, where shareholders will vote on a bylaw change allowing holders of 25% of shares to call special meetings and on activist-backed proposals for stricter executive stock retention. These votes are crucial for investor influence over company decisions and executive incentives, especially given Revvity's current valuation gap and recent stock decline. Investors are encouraged to monitor turnout and voting splits to understand the sh", "sentiment_score": 0.14055, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.402, "confidence": 0.4 } }, { "source": "alpha_vantage", "title": "Vanguard disaggregates holdings; Revvity (RVTY) filing shows 0 shares", "url": "https://www.stocktitan.net/sec-filings/RVTY/schedule-13g-a-revvity-inc-amended-passive-investment-disclosure-e9e4c6a75da5.html", "date": "2026-03-27", "summary": "The Vanguard Group has filed an amended Schedule 13G/A for Revvity (RVTY), disclosing 0 shares beneficially owned, representing 0% of the common stock. This filing indicates an internal realignment within Vanguard, where certain subsidiaries will now report beneficial ownership separately, as permitted by SEC Release No. 34-39538. The amendment clarifies a change in reporting structure rather than a change in underlying share counts.", "sentiment_score": 0.020222, "sentiment_label": "Neutral", "relevance_score": 0.314134, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Q4 Rundown: Sotera Health Company (NASDAQ:SHC) Vs Other Research Tools & Consumables Stocks", "url": "https://www.theglobeandmail.com/investing/markets/stocks/SHC/pressreleases/999492/q4-rundown-sotera-health-company-nasdaqshc-vs-other-research-tools-consumables-stocks/", "date": "2026-03-27", "summary": "This article provides a Q4 rundown of Sotera Health Company (NASDAQ:SHC) and other research tools & consumables stocks, highlighting their financial performance and market reception. Sotera Health exceeded analysts' expectations with strong revenues and a positive outlook, despite a subsequent stock dip. The article also reviews top performers like Bio-Techne and notes the weakest, Mettler-Toledo, while touching on broader market shifts driven by AI and geopolitical events.", "sentiment_score": 0.149347, "sentiment_label": "Neutral", "relevance_score": 0.733071, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Stifel maintains a hold rating on Revvity (RVTY)", "url": "http://www.msn.com/en-us/money/savingandinvesting/stifel-maintains-a-hold-rating-on-revvity-rvty/ar-AA1ZwgYa?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "date": "2026-03-27", "summary": "Stifel has reiterated its Hold rating on Revvity (RVTY). The article provides no further details on the reasons behind this rating or any financial analysis of the company.", "sentiment_score": 0.039057, "sentiment_label": "Neutral", "relevance_score": 0.341257, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Stifel Maintains a Hold Rating on Revvity (RVTY)", "url": "https://www.insidermonkey.com/blog/stifel-maintains-a-hold-rating-on-revvity-rvty-1725455/", "date": "2026-03-27", "summary": "Stifel maintained a Hold rating on Revvity (RVTY) with a $110 price target following a meeting with management. Revvity’s management expressed cautious optimism for 2026, forecasting low-single-digit growth in pharma and biotech, similar to 2025, driven by positive indicators such as increased high-content screening activity and improved biotech funding, but tempered by weak academic demand and short-term organic growth headwinds. The firm believes 2026 is a crucial year where macroeconomic reco", "sentiment_score": 0.094153, "sentiment_label": "Neutral", "relevance_score": 0.956982, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Revvity Inc. Stock: Navigating Life Sciences Headwinds and Q4 Earnings Pressure Ahead", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/revvity-inc-stock-navigating-life-sciences-headwinds-and-q4-earnings/68995674", "date": "2026-03-26", "summary": "Revvity Inc. shares are under pressure due to a life sciences sector slowdown, with investors anticipating the Q4 earnings report for signs of recovery in research funding and biopharma spending. Despite a flat year-over-year revenue in Q4 2025, the Diagnostics segment showed strength, offsetting declines in Discovery & Surety, while strategic acquisitions and a focus on recurring revenue streams provide resilience. The company's valuation is near historical averages, and its blend of diagnostic", "sentiment_score": -0.128092, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Q4 Research Tools & Consumables Earnings: Bio-Techne (NASDAQ:TECH) Earns Top Marks", "url": "https://stockstory.org/us/stocks/nasdaq/tech/news/earnings/q4-research-tools-and-consumables-earnings-bio-techne-nasdaqtech-earns-top-marks", "date": "2026-03-26", "summary": "Bio-Techne reported strong Q4 results, exceeding analyst expectations for revenue, though its stock saw an 18.5% decline post-reporting. The broader research tools & consumables sector had a satisfactory Q4, with revenues beating estimates by 1.2%, but share prices for many companies in the sector declined significantly. The article also reviews Q4 performance for other companies like Revvity, Mettler-Toledo, Sotera Health Company, and Agilent, highlighting varying results and market reactions a", "sentiment_score": 0.105983, "sentiment_label": "Neutral", "relevance_score": 0.740335, "sentiment": { "label": "positive", "score": 0.202, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "Revvity Inc. stock faces pressure amid life sciences sector slowdown as Q4 earnings loom", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/revvity-inc-stock-faces-pressure-amid-life-sciences-sector-slowdown-as-q4/68989833", "date": "2026-03-26", "summary": "Revvity Inc. is facing pressure due to a slowdown in the life sciences sector, marked by reduced research funding and biopharma spending cuts, which led to flat Q4 revenue and organic declines. US investors should monitor the upcoming Q4 results for insights into NIH funding impacts, biopharma R&D recovery, and the integration of acquisitions like BioLegend, especially given the company's significant US customer base and the resilience of its diagnostics segment. Despite sector headwinds, the co", "sentiment_score": -0.283533, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.477, "confidence": 0.48 } }, { "source": "alpha_vantage", "title": "10 Best Mid Cap Value Stocks to Buy in 2026", "url": "https://www.insidermonkey.com/blog/10-best-mid-cap-value-stocks-to-buy-in-2026hold-1724231/3", "date": "2026-03-25", "summary": "The article highlights XP Inc. (NASDAQ: XP) as one of the best mid-cap value stocks to buy in 2026, based on a recent analyst rating. Itau BBA raised its price target for XP Inc. to $22 and maintained a Market Perform rating, citing strong retail equity volume growth and expected FGC reimbursement reinvestment boosting revenues. XP Inc. offers diverse investment, credit, and pension products through its technology-enabled platform.", "sentiment_score": 0.014269, "sentiment_label": "Neutral", "relevance_score": 0.595331, "sentiment": { "label": "positive", "score": 0.765, "confidence": 0.77 } }, { "source": "alpha_vantage", "title": "Research Alert: CFRA Maintains Buy Rating On Shares Of Revvity, Inc.", "url": "https://www.moomoo.com/news/post/67411916/research-alert-cfra-maintains-buy-rating-on-shares-of-revvity", "date": "2026-03-25", "summary": "CFRA has reiterated its Buy rating on Revvity, Inc. shares. This indicates the firm's positive outlook on the company's stock performance.", "sentiment_score": 0.510617, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.527, "confidence": 0.53 } }, { "source": "alpha_vantage", "title": "10 Best Mid Cap Value Stocks to Buy in 2026", "url": "https://www.insidermonkey.com/blog/10-best-mid-cap-value-stocks-to-buy-in-2026hold-1724231/2", "date": "2026-03-25", "summary": "This article identifies Revvity, Inc. (NYSE:RVTY) as one of the best mid-cap value stocks for 2026, citing its health science solutions and moderate hedge fund interest. Stifel maintained a Hold rating on Revvity with a $110 price target, noting management's cautious optimism for moderate growth in pharma and biotech, despite some short-term headwinds like weak academic demand and slower software renewals. The firm views 2026 as pivotal for Revvity, with potential upside driven by macro-economic", "sentiment_score": 0.183644, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.765, "confidence": 0.77 } }, { "source": "alpha_vantage", "title": "10 Best Mid Cap Value Stocks to Buy in 2026", "url": "https://www.insidermonkey.com/blog/10-best-mid-cap-value-stocks-to-buy-in-2026hold-1724231/2/", "date": "2026-03-25", "summary": "This article, part of a larger list, focuses on Revvity, Inc. (NYSE:RVTY) as one of the best mid-cap value stocks to buy in 2026. Stifel maintained a Hold rating on the company with a $110 price target, following management's cautious yet optimistic outlook for 2026, driven by steady-state pharma/biotech growth and positive indicators despite some short-term headwinds like weak academic demand and China's market. Revvity offers advanced health science solutions across various segments.", "sentiment_score": 0.28494, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.765, "confidence": 0.77 } }, { "source": "alpha_vantage", "title": "Revvity Inc. stock faces pressure amid life sciences sector slowdown and looming Q4 earnings test", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/revvity-inc-stock-faces-pressure-amid-life-sciences-sector-slowdown-and/68980506", "date": "2026-03-25", "summary": "Revvity Inc. is facing stock pressure due to a slowdown in the life sciences sector, with flat Q4 revenue and organic declines in research tools. Despite resilience in its diagnostics segment and strategic acquisitions like BioLegend, the company's performance is sensitive to federal funding cycles and biopharma R&D spending. US investors are monitoring its upcoming full-year 2026 guidance and the integration of new acquisitions, viewing it as a value opportunity given its current valuation and ", "sentiment_score": -0.241438, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.402, "confidence": 0.4 } }, { "source": "alpha_vantage", "title": "Revvity Inc. stock faces pressure amid life sciences sector slowdown and acquisition integration cha", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/revvity-inc-stock-faces-pressure-amid-life-sciences-sector-slowdown-and/68977445", "date": "2026-03-24", "summary": "Revvity Inc. is experiencing pressure due to softening demand in the diagnostics and research markets, as well as challenges integrating recent acquisitions like BioLegend. Despite reaffirming full-year 2026 guidance, investors are skeptical given a 2.1% stock dip post-earnings and the broader sector's struggles post-pandemic. The company's Enterprise Services segment, focusing on newborn screening, provides some stability, while its stock trades at a discount, offering potential for patient inv", "sentiment_score": -0.244043, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.096, "confidence": 0.1 } }, { "source": "alpha_vantage", "title": "Revvity Inc. stock outperforms competitors on strong trading day", "url": "https://www.marketwatch.com/data-news/revvity-inc-stock-outperforms-competitors-on-strong-trading-day-c635d507-89e3a55108d3?mod=mw_quote_news&gaa_at=eafs&gaa_n=AWEtsqcvhCr1IQ4ygc6KiImC71KsrYZ2HgBOwRsA5qT0mjcsOyhDmXpbT79r&gaa_ts=69c203fc&gaa_sig=UOFfHyVHcgMA_1jR1PlBlV4_LomkcQA-2WaA_678ziv8JxWWQ8PP0AwIUDgHZca_4Fl33X_7Ez7nd1OkRNO91Q%3D%3D", "date": "2026-03-23", "summary": "Revvity Inc. (RVTY) shares rose 1.42% to $87.16 on Monday, outperforming its competitors and the broader market. This marked the third consecutive day of gains for the company's stock. The S&P 500 Index and the Dow Jones Industrial Average also saw significant gains during the trading session.", "sentiment_score": 0.468244, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.711, "confidence": 0.71 } }, { "source": "alpha_vantage", "title": "Tudor Investment Corp ET AL Acquires New Shares in Revvity Inc. $RVTY", "url": "https://www.marketbeat.com/instant-alerts/filing-tudor-investment-corp-et-al-acquires-new-shares-in-revvity-inc-rvty-2026-03-22/", "date": "2026-03-22", "summary": "Tudor Investment Corp ET AL recently acquired a new position of 172,601 shares, valued at approximately $15.13 million, in Revvity Inc. Institutional investors now own about 86.65% of Revvity stock. The company exceeded quarterly earnings estimates and provided optimistic FY2026 guidance, while analyst ratings are mixed, with a consensus \"Hold\" rating and a target price of $113.67.", "sentiment_score": 0.419275, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Reassessing Revvity (RVTY) Valuation After Strong Q4 Results And Weaker Guidance Versus Peers", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-rvty/revvity/news/reassessing-revvity-rvty-valuation-after-strong-q4-results-a/amp", "date": "2026-03-22", "summary": "Revvity (RVTY) is facing a reassessment of its valuation following strong Q4 results but weaker guidance compared to peers, coupled with new governance efforts. Despite trading well below recent highs and appearing 28.1% undervalued based on one narrative ($119.56 fair value), its current P/E ratio of 40.1x is significantly higher than its fair ratio and peer averages, indicating potential valuation risk. Investors are encouraged to review assumptions and consider other investment opportunities ", "sentiment_score": 0.219559, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.103, "confidence": 0.1 } }, { "source": "alpha_vantage", "title": "Reassessing Revvity (RVTY) Valuation After Strong Q4 Results And Weaker Guidance Versus Peers", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-rvty/revvity/news/reassessing-revvity-rvty-valuation-after-strong-q4-results-a", "date": "2026-03-22", "summary": "Revvity (RVTY) is experiencing volatility after strong Q4 results were followed by weaker peer comparisons and new governance efforts. Despite trading well below recent highs with a significant 1-year decline, the company's valuation narrative suggests it is 28.1% undervalued with a fair value of $119.56 due to expected margin expansion from a shifting product mix. However, a high P/E ratio of 40.1x, above both its fair ratio and peer average, indicates potential valuation risk.", "sentiment_score": -0.248483, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.103, "confidence": 0.1 } }, { "source": "alpha_vantage", "title": "Revvity Inc. stock faces pressure amid life sciences slowdown and acquisition integration challenges", "url": "https://www.ad-hoc-news.de/boerse/ueberblick/revvity-inc-stock-faces-pressure-amid-life-sciences-slowdown-and/68956170", "date": "2026-03-22", "summary": "Revvity Inc. reported mixed Q4 2025 results, with its diagnostics segment flatlining and overall revenue slightly missing analyst expectations, leading to an 8% stock drop. The company's conservative 2026 outlook, citing macro headwinds, further pressured shares despite strong operational discipline and progress on acquisition integration. While long-term prospects in precision medicine are positive, investors are wary of near-term growth challenges and increased competition.", "sentiment_score": -0.437473, "sentiment_label": "Bearish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": -0.026, "confidence": 0.03 } }, { "source": "alpha_vantage", "title": "Revvity Inc. stock faces pressure amid life sciences slowdown and acquisition integration challenges", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/revvity-inc-stock-faces-pressure-amid-life-sciences-slowdown-and/68956170", "date": "2026-03-22", "summary": "Revvity Inc. reported mixed Q4 2025 results, with revenue growth stalling in its diagnostics segment, leading to an over 8% drop in its NYSE stock price. While the company's Discovery & Analytical Solutions segment showed growth, conservative 2026 revenue guidance and ongoing integration challenges from its BioLegend acquisition are creating investor uncertainty. The article highlights the importance for DACH investors to monitor Revvity's European healthtech exposure and acquisition progress.", "sentiment_score": 0.038264, "sentiment_label": "Neutral", "relevance_score": 0.34866, "sentiment": { "label": "neutral", "score": -0.026, "confidence": 0.03 } }, { "source": "alpha_vantage", "title": "Revvity, Inc. Experiences Revision in Stock Evaluation Amid Mixed Market Indicators", "url": "https://www.marketsmojo.com/news/stocks-in-action/revvity-inc-technical-trend-shifts-from-mildly-bearish-to-sideways-amid-stock-price-decline-3903408", "date": "2026-03-21", "summary": "Revvity, Inc. has seen a decline in its stock price and performance compared to the S&P 500 over the past year, reflecting ongoing challenges in the Pharmaceuticals & Biotechnology sector. Technical indicators show a mixed performance, with bearish trends on some metrics and mildly bullish on others. The stock's current price is $85.76, significantly down from its 52-week high.", "sentiment_score": -0.291654, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "JPMorgan Chase & Co. Grows Stock Holdings in Revvity Inc. $RVTY", "url": "https://www.marketbeat.com/instant-alerts/filing-jpmorgan-chase-co-grows-stock-holdings-in-revvity-inc-rvty-2026-03-21/", "date": "2026-03-21", "summary": "JPMorgan Chase & Co. increased its stake in Revvity Inc. by 15.2% during the third quarter, bringing its total holdings to 511,360 shares valued at approximately $44.82 million. Revvity exceeded quarterly earnings expectations with $1.70 EPS on $772.06M revenue and provided a positive FY2026 EPS guidance. While analysts have a mixed \"Hold\" consensus rating with an average target of $113.67, the stock trades at $85.88 and offers a 0.3% dividend yield.", "sentiment_score": 0.25669, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.996735, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Revvity targets 2%-4% organic growth for 2025 as China diagnostics faces new policy headwinds", "url": "https://www.msn.com/en-us/money/companies/revvity-targets-2-4-organic-growth-for-2025-as-china-diagnostics-faces-new-policy-headwinds/ar-AA1JrHuk?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "date": "2026-03-21", "summary": "Revvity is targeting 2%-4% organic revenue growth in 2025 across its various business segments, with specific goals for diagnostics, life sciences, and applied markets. However, the company is facing new policy headwinds in China that are impacting its diagnostics business. Despite these challenges, Revvity anticipates returning to consistent organic growth in 2025.", "sentiment_score": -0.396598, "sentiment_label": "Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.382, "confidence": 0.38 } }, { "source": "alpha_vantage", "title": "Why (RVTY) Price Action Is Critical for Tactical Trading", "url": "https://news.stocktradersdaily.com/news_release/9/Why_RVTY_Price_Action_Is_Critical_for_Tactical_Trading_032126073802_1774093082.html", "date": "2026-03-21", "summary": "This article analyzes Revvity Inc. (NASDAQ: RVTY) stock, highlighting a neutral near-term sentiment and elevated downside risk. It presents AI-generated trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for support and resistance levels. The report emphasizes the importance of price action for tactical trading and offers access to real-time signals and institutional-grade analysis for subscribers.", "sentiment_score": 0.039633, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.318, "confidence": 0.32 } }, { "source": "alpha_vantage", "title": "How Investors May Respond To Revvity (RVTY) Cautious Outlook And Pushback On Executive Stock-Retention Rules", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-rvty/revvity/news/how-investors-may-respond-to-revvity-rvty-cautious-outlook-a", "date": "2026-03-20", "summary": "Shareholder activist John Chevedden proposed that Revvity's top five executives retain a significant portion of stock received through equity compensation until retirement, a proposal the company's board urges investors to reject. This pushback comes as Revvity provided a cautious full-year guidance, which was weaker than peers and led to a share price drop. The debate over executive stock retention highlights investor concerns about management incentives amidst efforts to balance cost controls,", "sentiment_score": -0.210049, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.103, "confidence": 0.1 } }, { "source": "alpha_vantage", "title": "How Investors May Respond To Revvity (RVTY) Cautious Outlook And Pushback On Executive Stock-Retention Rules", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-rvty/revvity/news/how-investors-may-respond-to-revvity-rvty-cautious-outlook-a/amp", "date": "2026-03-20", "summary": "Shareholder activist John Chevedden proposed that Revvity's top executives retain a significant portion of their stock until retirement, a proposal the board urges investors to vote against. This comes as Revvity provided cautious full-year guidance, contributing to a substantial share price drop, and leading investors to scrutinize management's balance of cost controls, capital returns, and growth investments amidst policy pressures in China. The article suggests that while Revvity aims for a p", "sentiment_score": -0.289836, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.103, "confidence": 0.1 } }, { "source": "alpha_vantage", "title": "Is Revvity Stock Underperforming the S&P 500?", "url": "https://markets.financialcontent.com/stocks/article/barchart-2026-3-20-is-revvity-stock-underperforming-the-s-and-p-500", "date": "2026-03-20", "summary": "Revvity, Inc. (RVTY), a life sciences and diagnostics company with a $9.5 billion market cap, has seen its stock slip 27.5% from its 52-week high. Over the past three months, RVTY gained 10.9%, underperforming the S&P 500 Index’s 3.3% fall, and also lagging over longer periods. Wall Street analysts, however, maintain a \"Moderate Buy\" rating with a potential upside of 39.2%.", "sentiment_score": -0.235405, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.2, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "Is Revvity Stock Underperforming the S&P 500?", "url": "https://www.barchart.com/story/news/859392/is-revvity-stock-underperforming-the-s-p-500", "date": "2026-03-20", "summary": "Revvity Inc. (RVTY), a global life sciences and diagnostics company with a $9.5 billion market cap, has shown mixed performance compared to the S&P 500. While its stock gained 10.9% in the past three months, outperforming the S&P 500's 3.3% fall, it has underperformed over longer periods, dipping 22% over 52 weeks versus the S&P 500's 16.4% return. Analysts maintain a \"Moderate Buy\" rating with a potential upside of 39.2%.", "sentiment_score": -0.223608, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.2, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "Research Tools & Consumables Q4 Earnings: Comparing Revvity (NYSE:RVTY)", "url": "https://www.bitget.com/amp/news/detail/12560605282422", "date": "2026-03-19", "summary": "The article reviews the Q4 earnings performance of companies in the research tools and consumables sector, focusing on Revvity (NYSE:RVTY), Bio-Techne (NASDAQ:TECH), Mettler-Toledo (NYSE:MTD), Agilent Technologies (NYSE:A), and Danaher (NYSE:DHR). While the sector overall saw revenues surpass analyst forecasts, share prices have struggled. The piece also touches on shifting market trends, from concerns over AI to geopolitical tensions' impact on investor focus.", "sentiment_score": -0.24271, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Research Tools & Consumables Companies Q4 Earnings: Comparing Revvity (NYSE:RVTY)", "url": "https://www.bitget.com/amp/news/detail/12560605282513", "date": "2026-03-19", "summary": "This article analyzes the Q4 earnings and performance of several companies in the research tools and consumables sector, with a focus on Revvity (NYSE:RVTY). While the sector generally saw positive revenue exceeding analyst forecasts, share prices experienced declines. The article highlights top and lowest performers like Bio-Techne (NASDAQ:TECH) and Mettler-Toledo (NYSE:MTD) respectively, and discusses market trends including concerns about AI and geopolitical risks impacting investment strateg", "sentiment_score": 0.010796, "sentiment_label": "Neutral", "relevance_score": 0.308415, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Revvity targets 2%-4% organic growth for 2025 as China diagnostics faces new policy headwinds", "url": "http://www.msn.com/en-us/money/companies/revvity-targets-2-4-organic-growth-for-2025-as-china-diagnostics-faces-new-policy-headwinds/ar-AA1JrHuk?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "date": "2026-03-18", "summary": "Revvity, a life sciences and diagnostics company, is projecting 2%-4% organic revenue growth for 2025. This outlook comes as the company navigates new policy challenges within the diagnostics sector in China. This forecast provides insight into Revvity's anticipated performance amidst current market conditions and regulatory changes.", "sentiment_score": -0.209162, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.382, "confidence": 0.38 } }, { "source": "alpha_vantage", "title": "Revvity (RVTY) awards stock options and RSUs to officer Anita Gonzales", "url": "https://www.stocktitan.net/sec-filings/RVTY/form-4-revvity-inc-insider-trading-activity-dfcd83902d3f.html", "date": "2026-03-18", "summary": "Revvity (RVTY) officer Anita Gonzales received new equity awards, including a non-qualified stock option for 4,576 shares at an exercise price of $86.635 and 1,600 time-based restricted stock units. Both awards are part of her compensation and are scheduled to fully vest on the second anniversary of the grant date. Following these grants, her direct common stock holdings in Revvity total 7,399 shares.", "sentiment_score": 0.045966, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.459, "confidence": 0.46 } }, { "source": "alpha_vantage", "title": "Revvity Inc. stock underperforms Wednesday when compared to competitors", "url": "https://www.marketwatch.com/data-news/revvity-inc-stock-underperforms-wednesday-when-compared-to-competitors-7aca5f4c-423acdce6b5a?gaa_at=eafs&gaa_n=AWEtsqcm1xp6Go619-AbFjK3RqY74_TrWBnccqD6mn23DW9Rvxf1_k3lYdFy&gaa_ts=69bb4ff8&gaa_sig=YWRWGEpCBcHkfTBmUOGMRukWllaAllPWBy7DzeTKp0PSDeW6svWcPLCisK2yrSLzAAgNKal8lzdjXoquT3vavw%3D%3D", "date": "2026-03-18", "summary": "Revvity Inc. (RVTY) shares dropped 2.79% to $84.93 on Wednesday, underperforming the broader market. This decline occurred during a poor trading session where the S&P 500 Index fell 1.36% and the Dow Jones Industrial Average dropped 1.63%, breaking Revvity's three-day winning streak.", "sentiment_score": -0.365246, "sentiment_label": "Bearish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.2, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "Research Tools & Consumables Stocks Q4 Results: Benchmarking Revvity (NYSE:RVTY)", "url": "https://www.tradingview.com/news/stockstory:7893c721c094b:0-research-tools-consumables-stocks-q4-results-benchmarking-revvity-nyse-rvty/", "date": "2026-03-18", "summary": "This article analyzes the Q4 2025 earnings for research tools and consumables stocks, with a focus on Revvity (NYSE: RVTY). It discusses the sector's performance, key challenges and tailwinds, and individual company results. While Revvity reported strong revenue, its guidance was the weakest in the group, leading to a stock decline.", "sentiment_score": -0.257317, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Research Tools & Consumables Stocks Q4 Results: Benchmarking Revvity (NYSE:RVTY)", "url": "https://stockstory.org/us/stocks/nyse/rvty/news/earnings/research-tools-and-consumables-stocks-q4-results-benchmarking-revvity-nyservty", "date": "2026-03-17", "summary": "This article analyzes the Q4 2025 earnings performance of Revvity (NYSE:RVTY) and other research tools & consumables stocks. While Revvity exceeded revenue expectations, its full-year guidance was the weakest in the group, leading to a stock decline. The article also reviews Bio-Techne as the best performer and Mettler-Toledo as the weakest, alongside results for Bruker and Waters Corporation.", "sentiment_score": -0.31668, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "CRL,PBE Volatility & Greeks", "url": "https://finviz.com/quote.ashx?t=CRL%2CPBE&ta=1&p=m&ty=ocv&r=y5&ov=list_strike&bd=bd-piechart&tt=tt-map&s=220", "date": "2026-03-16", "summary": "This article provides detailed financial and news information for Charles River Laboratories International Inc (CRL) and Invesco Biotechnology & Genome ETF (PBE). It includes stock performance metrics, insider trading activity for CRL, and a comprehensive list of news articles and analyst ratings for both, offering a snapshot of their market positions and recent events.", "sentiment_score": 0.129293, "sentiment_label": "Neutral", "relevance_score": 0.555239, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Emerald Growth Equity Strategy Sold Revvity (RVTY) in Q4", "url": "https://www.insidermonkey.com/blog/emerald-growth-equity-strategy-sold-revvity-rvty-in-q4-1717681/", "date": "2026-03-16", "summary": "Emerald Growth Equity Strategy sold its position in Revvity, Inc. (RVTY) during Q4 2025 due to limited visibility into the company's business trajectory and management's failure to execute its strategic plan. Despite Revvity's presence in 35 hedge fund portfolios, Emerald Growth Equity believes AI stocks offer greater potential for higher returns in a shorter timeframe. The firm's Growth Equity Strategy returned +3.1% (gross) and +3.0% (net) in 2025.", "sentiment_score": -0.44842, "sentiment_label": "Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.382, "confidence": 0.38 } }, { "source": "alpha_vantage", "title": "[ARS] REVVITY, INC. SEC Filing", "url": "https://www.stocktitan.net/sec-filings/RVTY/ars-revvity-inc-sec-filing-cd5213cc79f9.html", "date": "2026-03-16", "summary": "This article announces an ARS SEC filing by Revvity, Inc. (RVTY) on March 16, 2026. The filing is categorized with low impact and neutral sentiment, and a link to the full PDF document on SEC EDGAR is provided. The article also includes an overview of RVTY's stock rankings, recent news, and other SEC filings.", "sentiment_score": 0.035842, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Winners And Losers Of Q4: Waters Corporation (NYSE:WAT) Vs The Rest Of The Research Tools & Consumables Stocks", "url": "https://www.barchart.com/story/news/777016/winners-and-losers-of-q4-waters-corporation-nysewat-vs-the-rest-of-the-research-tools-consumables-stocks", "date": "2026-03-16", "summary": "This article analyzes the Q4 performance of Waters Corporation (NYSE:WAT) and other research tools & consumables stocks. Waters Corporation reported declining revenues but exceeded next quarter's guidance, while Bio-Techne (NASDAQ:TECH) had a strong quarter outperforming expectations. Mettler-Toledo (NYSE:MTD) and Revvity (NYSE:RVTY) experienced slower quarters with mixed results, and Agilent (NYSE:A) had a mixed quarter with aligned revenue expectations.", "sentiment_score": -0.209342, "sentiment_label": "Somewhat-Bearish", "relevance_score": 0.649212, "sentiment": { "label": "negative", "score": -0.077, "confidence": 0.08 } }, { "source": "alpha_vantage", "title": "Revvity Inc. (NYSE:RVTY) Given Consensus Recommendation of \"Hold\" by Brokerages", "url": "https://www.marketbeat.com/instant-alerts/revvity-inc-nyservty-given-consensus-recommendation-of-hold-by-brokerages-2026-03-16/", "date": "2026-03-16", "summary": "Revvity Inc. (NYSE:RVTY) has received a consensus \"Hold\" recommendation from fourteen brokerages, with an average one-year price target of $113.67. The company recently reported strong quarterly earnings, exceeding analyst estimates for both EPS and revenue, and announced a quarterly dividend of $0.07 per share. Several analysts have updated their ratings and price targets for Revvity based on these financial results.", "sentiment_score": 0.127083, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "EdgePoint Investment Group Inc. Acquires 1,784,620 Shares of Revvity Inc. $RVTY", "url": "https://www.marketbeat.com/instant-alerts/filing-edgepoint-investment-group-inc-acquires-1784620-shares-of-revvity-inc-rvty-2026-03-15/", "date": "2026-03-15", "summary": "EdgePoint Investment Group Inc. significantly increased its stake in Revvity Inc. by 26.3% in Q3, purchasing over 1.7 million shares and making Revvity its 8th largest holding. Revvity recently surpassed its quarterly earnings estimates and forecasted strong FY2026 EPS, while also announcing a quarterly dividend. Analysts maintain a \"Hold\" consensus rating with a target price of $113.67 for the company.", "sentiment_score": 0.447435, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Analysts Have Conflicting Sentiments on These Healthcare Companies: Revvity (RVTY) and Candel Therapeutics (CADL)", "url": "https://www.theglobeandmail.com/investing/markets/stocks/RVTY-N/pressreleases/752691/analysts-have-conflicting-sentiments-on-these-healthcare-companies-revvity-rvty-and-candel-therapeutics-cadl/", "date": "2026-03-14", "summary": "This article highlights contrasting analyst sentiments for two healthcare companies: Revvity (RVTY) and Candel Therapeutics (CADL). Stifel Nicolaus maintained a \"Hold\" rating for Revvity with a $110.00 price target, while Canaccord Genuity reiterated a \"Buy\" rating for Candel Therapeutics with a $25.00 price target, suggesting a significant upside.", "sentiment_score": 0.264272, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.402, "confidence": 0.4 } }, { "source": "alpha_vantage", "title": "Korea Investment CORP Sells 29,300 Shares of Revvity Inc. $RVTY", "url": "https://www.marketbeat.com/instant-alerts/filing-korea-investment-corp-sells-29300-shares-of-revvity-inc-rvty-2026-03-13/", "date": "2026-03-13", "summary": "Korea Investment CORP decreased its stake in Revvity Inc. by 41.1% in the third quarter, selling 29,300 shares and retaining 41,965 shares valued at approximately $3.68 million. Despite other institutional investors increasing their holdings and Revvity beating quarterly earnings expectations, the stock currently holds an average \"Hold\" rating from analysts with an average target price of $113.67 against its current trading price around $84.63. Revvity recently announced a quarterly dividend of ", "sentiment_score": 0.181792, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Revvity Inc. $RVTY Shares Sold by Capital Research Global Investors", "url": "https://www.marketbeat.com/instant-alerts/filing-revvity-inc-rvty-shares-sold-by-capital-research-global-investors-2026-03-13/", "date": "2026-03-13", "summary": "Capital Research Global Investors significantly reduced its stake in Revvity Inc. (RVTY) by 99.8% in the third quarter, selling over 2.6 million shares. Despite this, other institutions increased their holdings, with institutional investors now owning 86.65% of the company. Revvity recently surpassed quarterly EPS and revenue estimates, provided positive FY2026 guidance, and analysts currently have a consensus \"Hold\" rating with a price target of $113.67.", "sentiment_score": 0.113852, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Stifel reiterates Hold on Revvity stock, keeps $110 price target", "url": "https://www.investing.com/news/analyst-ratings/stifel-reiterates-hold-on-revvity-stock-keeps-110-price-target-93CH-4559986", "date": "2026-03-13", "summary": "Stifel maintained a Hold rating on Revvity Inc (NYSE:RVTY) with a $110.00 price target after a non-deal roadshow with management. While management expressed cautious optimism regarding certain end markets and stronger portfolio segments, they expect pharmaceutical and biotech growth to remain in the low single-digit range for 2026. The stock is currently trading near its 52-week low and appears undervalued, suggesting potential upside if macroeconomic conditions or biotech funding accelerate.", "sentiment_score": 0.095246, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Stifel reiterates Hold on Revvity stock, keeps $110 price target", "url": "https://m.investing.com/news/analyst-ratings/stifel-reiterates-hold-on-revvity-stock-keeps-110-price-target-93CH-4559986?ampMode=1", "date": "2026-03-13", "summary": "Stifel has reiterated a Hold rating on Revvity Inc (NYSE:RVTY) with a $110 price target, following a roadshow with management. While management expressed cautious optimism for 2026, assuming low single-digit growth for pharma and biotech, Stifel sees potential for upside if macroeconomic conditions or biotech funding accelerate. The stock is currently trading near its 52-week low and is considered undervalued according to InvestingPro analysis, despite recent strong Q4 2025 financial results and", "sentiment_score": 0.046002, "sentiment_label": "Neutral", "relevance_score": 0.319555, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "A Look At Mettler-Toledo International (MTD) Valuation After Recent Institutional Selling And Sector Weakness", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-mtd/mettler-toledo-international/news/a-look-at-mettler-toledo-international-mtd-valuation-after-r", "date": "2026-03-12", "summary": "Mettler-Toledo International (MTD) has experienced a 7-day losing streak, dropping 12% due to institutional selling and sector weakness, despite a positive longer-term share price return. The stock is currently trading below its fair value estimate of $1,501, suggesting it might be undervalued, driven by strong demand for its automation and digitalization solutions. However, its P/E ratio of 28.7x appears expensive compared to its fair ratio and peer average, indicating differing signals about i", "sentiment_score": 0.036022, "sentiment_label": "Neutral", "relevance_score": 0.627464, "sentiment": { "label": "negative", "score": -0.421, "confidence": 0.42 } }, { "source": "pubmed", "pmid": "41900218", "title": "Integrated Experimental-Computational Framework for Drug Transport Quantification in 3D Microtissues™.", "authors": "Fariha R et al.", "journal": "Micromachines", "date": "2026 Mar 9", "url": "https://pubmed.ncbi.nlm.nih.gov/41900218/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41877199", "title": "Machine says go, doctor says no: an ecological momentary assessment analysis examining clinicians' perceptions of, and their antibiotic prescribing behaviour when using rapid molecular diagnostic tests in intensive care.", "authors": "Stewart SF et al.", "journal": "Antimicrobial resistance and infection control", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41877199/", "sentiment": { "label": "positive", "score": 0.494, "confidence": 0.49 } }, { "source": "pubmed", "pmid": "41858248", "title": "Prevalence and Predictors of Tuberculosis in Adults and Adolescents With Sputum Trace Ultra Results in 2 High-Burden Clinical Settings.", "authors": "Visek C et al.", "journal": "Clinical infectious diseases : an official publication of the Infectious Diseases Society of America", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41858248/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41831164", "title": "PDXK Mutation Causes a Late-Onset Pyridoxal 5'-Phosphate-Responsive Peripheral Neuropathy Preceded by Neonatal Seizures: Authors' Reply.", "authors": "Arora A et al.", "journal": "Indian journal of pediatrics", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41831164/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41807232", "title": "Inhalable Ultrasound Contrast Agent with Induced Microbubble Destruction and Associated Biological Effects on the Respiratory Epithelium, In Vitro.", "authors": "Weitz AS et al.", "journal": "Ultrasound in medicine & biology", "date": "2026 Mar 9", "url": "https://pubmed.ncbi.nlm.nih.gov/41807232/", "sentiment": { "label": "negative", "score": -0.572, "confidence": 0.57 } }, { "source": "pubmed", "pmid": "41774927", "title": "Measuring the Degree of Labeling of Antibody-Dye Conjugates with a Single-Molecule-Sensitive Digital Flow Cytometer.", "authors": "Cheng Y et al.", "journal": "Analytical chemistry", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41774927/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41739160", "title": "[On the urgency of treating ophthalmic emergencies].", "authors": "Seitz IP et al.", "journal": "Die Ophthalmologie", "date": "2026-03-30", "url": "https://pubmed.ncbi.nlm.nih.gov/41739160/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41493740", "title": "Cost Comparison of Repeat Placental Growth Factor-Based Testing in Women with Suspected Preterm Pre-eclampsia, Compared to Usual Care: The PARROT-2 Trial.", "authors": "Hurrell A et al.", "journal": "PharmacoEconomics - open", "date": "2026-03-30", "url": "https://pubmed.ncbi.nlm.nih.gov/41493740/", "sentiment": { "label": "positive", "score": 0.599, "confidence": 0.6 } }, { "source": "pubmed", "pmid": "41468708", "title": "D-threo-chloramphenicol: tritium labelling at high specific activity.", "authors": "Carr S et al.", "journal": "Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine", "date": "2026-03-30", "url": "https://pubmed.ncbi.nlm.nih.gov/41468708/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41355705", "title": "Angiogenic Biomarkers and Neonatal Outcomes in Suspected Preeclampsia: Retrospective Cohort Study.", "authors": "Fung GPG et al.", "journal": "BJOG : an international journal of obstetrics and gynaecology", "date": "2026-03-30", "url": "https://pubmed.ncbi.nlm.nih.gov/41355705/", "sentiment": { "label": "negative", "score": -0.226, "confidence": 0.23 } }, { "source": "pubmed", "pmid": "41175037", "title": "In Vivo Performance of Airway and Lung Ultrasound Enhanced via Inhalable Contrast Agents.", "authors": "Weitz AS et al.", "journal": "Ultrasonic imaging", "date": "2026-03-30", "url": "https://pubmed.ncbi.nlm.nih.gov/41175037/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "OGM_BionanoGenomics", "title": "The Power of Three“Revvity", "text": "**“Revvity is proud to integrate and market Bionano’s VIA™ software within our newborn sequencing research workflow.** This collaboration is intended to enhance CNV detection and interpretation alongside NGS, giving clinical and research laboratories a streamlined, turnkey option that lowers commercial friction for adopting complementary OGM capabilities.”\n\n**“NVIDIA is collaborating with Bionano to deliver GPU‑accelerated solutions for OGM secondary analysis that materially reduce processing ti", "author": "Incognew01", "score": 2, "num_comments": 0, "date": "2026-03-21", "url": "https://reddit.com/r/OGM_BionanoGenomics/comments/1rzpqn2/the_power_of_threerevvity/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "EverHint", "title": "EverHint Lens - Hims & Hers Health, Inc. (HIMS) - Yahoo Top Gainer (+40%) Stock Analysis - March 09, 2026", "text": "**Analysis Date** : 2026-03-09 \n**Sector** : Healthcare \n**Industry** : Medical - Equipment & Services \n**Exchange** : NYSE\n\n## Executive Summary\n\nHims & Hers Health, Inc. is currently trading at **$22.12** (🟢 +40.52% today) with a market capitalization of **$4.86B**.\n\nHims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase", "author": "Mamuthone125", "score": 1, "num_comments": 0, "date": "2026-03-09", "url": "https://reddit.com/r/EverHint/comments/1rp5lp9/everhint_lens_hims_hers_health_inc_hims_yahoo_top/", "sentiment": { "label": "positive", "score": 0.202, "confidence": 0.2 } }, { "source": "reddit", "subreddit": "EverHint", "title": "EverHint – EMA10 × Price × MACD – Top 10 Buy Signals for Mar 04, 2026", "text": "## What This Signal Is (Quick)\n\nThis is an **experimental strategy** that combines two bullish signals occurring on the **same day** :\n\n 1. **Price crosses above EMA10 from below**\n\n * Yesterday: `price_prev <= ema10_prev`\n * Today: `price > ema10`\n * Indicates price breaking above short-term trend\n 2. **MACD Line crosses above Signal Line from below**\n\n * Yesterday: `macd_line_prev <= macd_signal_prev`\n * Today: `macd_line > macd_signal`\n * Confirms bullish momentum sh", "author": "Mamuthone125", "score": 1, "num_comments": 0, "date": "2026-03-05", "url": "https://reddit.com/r/EverHint/comments/1rl709d/everhint_ema10_price_macd_top_10_buy_signals_for/", "sentiment": { "label": "positive", "score": 0.202, "confidence": 0.2 } }, { "source": "reddit", "subreddit": "OGM_BionanoGenomics", "title": "Revvity Acquires ACD/Labs", "text": "ACD/Labs is a Toronto software company that makes analytical‑chemistry tools (like Spectrus and Percepta) used by pharma, chemical, and materials researchers worldwide; it has a global customer base and a few hundred employees.\n\nRevvity already has a **software marketing agreement** to market Bionano’s **VIA** to Revvity’s NGS customers, specifically to add **Copy Number Variant assessment** into newborn sequencing workflows.\n\nRevvity’s purchase of ACD/Labs should **help, not hurt**, Revvity’s e", "author": "Incognew01", "score": 1, "num_comments": 1, "date": "2026-03-15", "url": "https://reddit.com/r/OGM_BionanoGenomics/comments/1rubehz/revvity_acquires_acdlabs/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "CrownElectrokinetics", "title": "The Power of Three“Revvity", "text": "", "author": "Incognew01", "score": 1, "num_comments": 0, "date": "2026-03-21", "url": "https://reddit.com/r/CrownElectrokinetics/comments/1rzpqtk/the_power_of_threerevvity/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "CrownElectrokinetics", "title": "Revvity Acquires ACD/Labs", "text": "", "author": "Incognew01", "score": 1, "num_comments": 0, "date": "2026-03-15", "url": "https://reddit.com/r/CrownElectrokinetics/comments/1rubeno/revvity_acquires_acdlabs/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "TMKOC", "title": "25,000rs envelope arc", "text": "I don't think jetha should've given money to that guy for beshisht mhataras mistake \n\nBhidu, popu and champhuck couldn't even wait for a day and jetha had to pay for it ", "author": "Shiroyasha_a", "score": 170, "num_comments": 15, "date": "2026-03-07", "url": "https://reddit.com/r/TMKOC/comments/1rneqke/25000rs_envelope_arc/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "stockstobuytoday", "title": "What are you guys looking at today?", "text": "I'm still holding ANNA, but what else are you guys looking at?", "author": "cabinontheland", "score": 12, "num_comments": 25, "date": "2026-03-06", "url": "https://reddit.com/r/stockstobuytoday/comments/1rmd1fc/what_are_you_guys_looking_at_today/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "PAX", "title": "Send a Free Postcard at PAX East 💌 Pelican Post (Booth #20084)", "text": "Send a free postcard from Port Pleasant 💌\n\nWe’re at Booth #20084 with MAGIC Spell Studios, where you can write and send a real postcard (we’ll cover postage!) straight from the world of Pelican Post.\n\nWe wanted to bring the world of Pelican Post to life at PAX, creating a space centered around community and connection.\n\nWe also have a live demo running all weekend, so you can experience our cozy, narrative-driven mail delivery game firsthand.\n\nCome stop by, play, and experience a piece of Port P", "author": "PelicanPost", "score": 73, "num_comments": 11, "date": "2026-03-25", "url": "https://reddit.com/r/PAX/comments/1s3r5az/send_a_free_postcard_at_pax_east_pelican_post/", "sentiment": { "label": "positive", "score": 0.818, "confidence": 0.82 } }, { "source": "reddit", "subreddit": "NIPT", "title": "Any experts on Z-scores?", "text": "My NIPT results is positive for trisomy 21. I know that only an amnio provides certainty. But after three miscarriages, I don’t want to take the risk. I’ve done some research on Z-scores. The manufacturer Vanadis/Revvity provides a table for the positive predictive value (PPV). According to this, the PPV is 50% for a Z-score <5. The lab and my doctor aren’t aware of this and say a positive result is 99% accurate. Also, there’s no fetal fraction listed. Could the Z-score be low because there’s on", "author": "Thin_Palpitation8768", "score": 1, "num_comments": 17, "date": "2026-03-20", "url": "https://reddit.com/r/NIPT/comments/1ryrdnl/any_experts_on_zscores/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "OGM_BionanoGenomics", "title": "Reasons Behind the Uptick", "text": "While there’s no single flashy headline driving it, the underlying reasons seem pretty clear. Hospitals and research centers tend to move quietly at first, but the combination of the new CPT codes, growing validation data, and partnerships with companies like Revvity, NVIDIA, and Hangzhou Diagens suggests that more institutions are finally taking OGM seriously. These aren’t casual collaborations…they signal that the technology is scalable, clinically relevant, and increasingly aligned with where", "author": "Incognew01", "score": 1, "num_comments": 1, "date": "2026-03-23", "url": "https://reddit.com/r/OGM_BionanoGenomics/comments/1s1qqp2/reasons_behind_the_uptick/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "EverHint", "title": "EverHint – EMA10 × EMA30 Crossover – Top 10 Buy and Top 10 Sell Signals for Mar 25, 2026", "text": "## What This Signal Is (Quick)\n\nThis strategy detects **fresh crossovers** between the 10-day exponential moving average (EMA10) and the 30-day exponential moving average (EMA30):\n\n * **Buy Signal (EMA10_x_EMA30_Buy)** : EMA(10) crosses **above** EMA(30) on today's close\n\n * Short-term momentum overtakes medium-term trend\n * Suggests acceleration in upward price movement\n * Ideal for swing trading (1-4 week holding periods)\n * **Sell Signal (EMA10_x_EMA30_Sell)** : EMA(10) crosses **b", "author": "Mamuthone125", "score": 1, "num_comments": 0, "date": "2026-03-26", "url": "https://reddit.com/r/EverHint/comments/1s3xb55/everhint_ema10_ema30_crossover_top_10_buy_and_top/", "sentiment": { "label": "positive", "score": 0.382, "confidence": 0.38 } }, { "source": "reddit", "subreddit": "EverHint", "title": "EverHint – EMA10 × Price × MACD – Top 10 Buy Signals for Mar 24, 2026", "text": "## What This Signal Is (Quick)\n\nThis is an **experimental strategy** that combines two bullish signals occurring on the **same day** :\n\n 1. **Price crosses above EMA10 from below**\n\n * Yesterday: `price_prev <= ema10_prev`\n * Today: `price > ema10`\n * Indicates price breaking above short-term trend\n 2. **MACD Line crosses above Signal Line from below**\n\n * Yesterday: `macd_line_prev <= macd_signal_prev`\n * Today: `macd_line > macd_signal`\n * Confirms bullish momentum sh", "author": "Mamuthone125", "score": 2, "num_comments": 0, "date": "2026-03-25", "url": "https://reddit.com/r/EverHint/comments/1s32a08/everhint_ema10_price_macd_top_10_buy_signals_for/", "sentiment": { "label": "positive", "score": 0.202, "confidence": 0.2 } }, { "source": "reddit", "subreddit": "InternshipDrops", "title": "Today’s tech internships: software, data, and ML roles", "text": "See more on \\[internshipdaily.com/internships?category=software\\_engineering\\](https://internshipdaily.com/internships?category=software\\_engineering)\n\nHey everyone, some solid tech internships posted today. No Google/Meta this time, but plenty of hands-on gigs in software, data, and ML.\n\n\\*\\*tateandlyle - Master Data Trainee\\*\\*\nLodz, poland\nhttps://tateandlyle.wd3.myworkdayjobs.com/en-US/tlcareers/job/Lodz/Master-Data-Trainee\\_JREQ10134\n\n\\*\\*vanderlande - Internship: AI Workbench Development &", "author": "Altruistic_Hunt_4369", "score": 5, "num_comments": 0, "date": "2026-03-20", "url": "https://reddit.com/r/InternshipDrops/comments/1rz9u31/todays_tech_internships_software_data_and_ml_roles/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "OGM_BionanoGenomics", "title": "Bionano: Stuctural Variant Diva", "text": "**Bionano Genomics** looks well positioned to lead in **structural variant** detection by combining its optical mapping platform with two powerful partners: **NVIDIA** and **Revvity**. NVIDIA’s GPUs and genomics software can speed up the heavy data analysis needed to find large DNA changes, turning days of computation into hours and making results more consistent and scalable for labs. Revvity brings lab workflows, distribution, and credibility that can help embed Bionano’s VIA software into rou", "author": "Incognew01", "score": 1, "num_comments": 0, "date": "2026-03-02", "url": "https://reddit.com/r/OGM_BionanoGenomics/comments/1rirykd/bionano_stuctural_variant_diva/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } } ] } }